Elicio Therapeutics, Inc. (ELTX) 株式分析

企業概要

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to the development of immunotherapies designed for the treatment of cancer. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a high level of research and development intensity and reliance on successful clinical trial outcomes to generate future value. As of the latest data, the company maintains a market capitalization of $189.30M and employs 33 individuals to execute its strategic initiatives. The market cap figure of $189.30M combined with the absence of reported annual revenue indicates that the firm is currently in a pre-revenue growth phase, where valuation is driven primarily by potential future cash flows from its product pipeline rather than current operational earnings. This structural characteristic is typical for early-stage biotech entities that have not yet commercialized their lead assets, meaning the current market valuation reflects investor sentiment regarding the potential of its lead product candidate, ELI-002, rather than established profitability.

財務健全性

The reported revenue for the trailing twelve months is N/A, reflecting the company's stage of development, while the net income for the same period stands at $-39,571,000, and the EBITDA is recorded at $-37,510,000. The substantial gap between the non-existent revenue and the significant net loss of $-39,571,000 reveals a cost structure dominated by heavy research and development expenditures, clinical trial costs, and general administrative expenses incurred in pursuit of regulatory approval. Free cash flow is reported at $-21,666,376, indicating that the company is consuming cash reserves to fund its operations and development programs, which limits immediate financial flexibility but is necessary for reaching commercialization milestones. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which is consistent with a company that has not yet generated significant sales volume to cover its fixed and variable costs. On the balance sheet, the company holds $18.56M in cash against $14.51M in debt, resulting in a debt-to-equity ratio of 887.04, which suggests a highly leveraged position relative to equity but indicates sufficient cash coverage for immediate obligations. The current ratio of 2.38 demonstrates that the company possesses sufficient liquid assets to cover its short-term liabilities more than twice over, providing a buffer against liquidity risks despite the lack of operating cash flow. Return on Equity is listed as N/A due to the absence of attributable income, while the Return on Assets stands at -87.2%, signaling that the company's asset base is currently generating negative returns as it is invested in long-term development rather than revenue-generating activities.

バリュエーション評価

The trailing P/E ratio is listed as N/A due to the company's net losses, whereas the forward P/E is calculated at -7.35, a metric that is difficult to interpret in isolation for a loss-making firm but highlights the significant disparity between current market pricing and expected future earnings. The price-to-book ratio is exceptionally high at 111.85, indicating that the market is valuing the company's equity at a massive premium over its book value, a phenomenon common in biotech firms where intangible assets like intellectual property and pipeline potential are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio, which is N/A due to lack of revenue, and the EV/EBITDA of -4.94, further underscore that traditional valuation models are less applicable here, forcing reliance on pipeline-based valuation methodologies. The stock has traded within a 52-week range with a high of $14.93 and a low of $4.60; without a specific current price provided in the source data, the positioning relative to this range cannot be numerically calculated, but the wide spread suggests significant price volatility driven by clinical trial news and market sentiment. The beta value of 1.88 indicates that the stock's price volatility is nearly double that of the broader market, reflecting the high risk and uncertainty inherent in investing in clinical-stage biotechnology companies where outcomes can lead to sharp price swings.

Growth & Income

The revenue growth year-over-year is listed as N/A, and earnings growth year-over-year is also N/A, as the company has not yet generated positive revenue or consistent earnings to calculate meaningful growth rates. In the absence of positive earnings growth, there is no basis to compare earnings growth against revenue growth, as the primary focus remains on the progression of clinical trials rather than expanding profit margins. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that any generated earnings or existing cash reserves are not distributed to shareholders but are instead reinvested into the company's research, development, and operational infrastructure. Consequently, the overall growth and income profile of Elicio Therapeutics, Inc. is characterized by a complete reliance on capital appreciation and the potential future success of its immunotherapy candidates, offering no current income stream for investors and exposing them to the binary risks associated with clinical-stage asset development.